AstraZeneca plc (NYSE: AZN) presented high-level results from a prespecified interim analysis of the Phase III VOLGA clinical trial at the 2026 European Society for Medical Oncology (ESMO) Congress, showing that perioperative Imfinzi (durvalumab) combined with neoadjuvant enfortumab vedotin (EV) delivered statistically significant and clinically meaningful improvements in both event-free survival (EFS) and overall survival (OS) versus standard of care in patients with muscle-invasive bladder cancer (MIBC) who are inelig for or refuse cisplatin-based chemotherapy.
Trial Snapshot – VOLGA Phase III
| Item | Detail |
|---|---|
| Sponsor | AstraZeneca plc (NYSE: AZN) |
| Trial | VOLGA, Phase III – prespecified interim analysis |
| Setting | Perioperative: neoadjuvant EV + Imfinzi, followed by surgery and adjuvant Imfinzi |
| Population | MIBC patients ineligible for or refusing cisplatin-based chemotherapy |
| Primary Endpoint | Event-free survival (EFS) – met with statistical significance |
| Key Secondary Endpoint | Overall survival (OS) – statistically significant improvement |
| Presented At | 2026 ESMO Congress |
Clinical Evidence – Prespecified Interim Analysis
| Endpoint | Imfinzi + EV Arm | Control Arm | Relative Benefit |
|---|---|---|---|
| EFS Hazard Ratio | – | – | 49% risk reduction (HR 0.51; 95% CI: 0.38–0.67; p<0.0001) |
| Median EFS (Estimated) | Not yet reached | 12.1 months | – |
| 2-Year EFS Rate | 64% | 45% | +19 percentage points |
| OS Hazard Ratio | – | – | 42% risk reduction (HR 0.58; 95% CI: 0.40–0.83; p=0.0027) |
| Median OS (Estimated) | Not yet reached | Not yet reached | – |
- Composite EFS Endpoint: The EFS endpoint captured disease progression, recurrence, failure to undergo surgery, or death — the combination reduced this composite risk by nearly half versus control.
- Dual-Endpoint Significance: Achieving both EFS and OS significance at interim analysis is a high bar in perioperative oncology, strengthening the regimen’s evidence base for regulatory and guideline adoption.
Market Impact & Outlook
- Unmet Need Addressed: Cisplatin-ineligible patients represent a substantial share of the MIBC population — historically left with limited perioperative options — giving the Imfinzi + EV regimen a clear positioning niche.
- Franchise Expansion: The win extends Imfinzi’s footprint into another tumor type and into the perioperative setting, complementing AstraZeneca’s growing immuno-oncology and ADC-linked pipeline.
- Combination Strategy Validation: Pairing a PD-L1 inhibitor with an antibody-drug conjugate in the neoadjuvant window reinforces AstraZeneca’s combination-first development model in early-stage disease.
- Next Steps: Not disclosed in the interim release; regulatory submissions and longer-term follow-up data are expected to shape commercial trajectory.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the VOLGA trial, the Imfinzi plus enfortumab vedotin combination, and AstraZeneca’s oncology portfolio. These results are from a prespecified interim analysis; actual outcomes may differ due to risks including final data maturity, regulatory review decisions, reimbursement dynamics, and competitive developments in muscle-invasive bladder cancer treatment.-Fineline Info & Tech
